High Lp(a) Raises Absolute Heart Disease Risk Even More Sharply After Age 70
A large Danish cohort shows Lp(a)'s relative cardiovascular risk is constant across the lifespan, but absolute risk explodes in older adults.
Summary
A study of over 103,000 Danish adults found that elevated lipoprotein(a) — a genetic risk factor for heart disease — carries the same relative risk boost at every age, but the absolute danger grows dramatically with age. For every 50 mg/dL increase in Lp(a), the additional heart disease cases per 1,000 person-years rose from 0.3 in those aged 20–49 up to 4.5 in those aged 80–100. This means older adults with high Lp(a) face a far greater real-world threat than younger people with the same levels. The findings reinforce that Lp(a) screening and emerging lowering therapies may deliver their greatest benefit to older populations, where cardiovascular events are far more frequent.
Detailed Summary
Lipoprotein(a), or Lp(a), is a genetically determined lipid particle increasingly recognized as a causal driver of atherosclerotic cardiovascular disease (ASCVD). Unlike LDL cholesterol, Lp(a) levels are largely set by genetics and resist conventional lifestyle modification. New therapies capable of dramatically lowering Lp(a) are now in late-stage development, making it critical to understand who stands to benefit most — and when across the lifespan.
Researchers analyzed data from 103,341 participants (57,899 women and 45,442 men) in the Copenhagen General Population Study, ranging in age from 20 to 100 years. Over a median follow-up of 12.5 years, 9,091 individuals developed ASCVD. The team calculated both relative (hazard ratios) and absolute (incidence rate) risk increases associated with Lp(a) levels, stratified by age decade and sex.
The key finding is a striking divergence between relative and absolute risk. Hazard ratios per 50 mg/dL higher Lp(a) were remarkably consistent across all age groups and both sexes, ranging from 1.12 to 1.18 — meaning Lp(a) is proportionally just as dangerous at 30 as at 85. But absolute incidence increases tell a different story: the additional ASCVD cases attributable to very high Lp(a) (90–426 mg/dL) jumped from roughly 3.2 per 1,000 person-years in young adults to 48 per 1,000 person-years in those aged 80–100. Men experienced slightly higher absolute increases than women across all age groups.
For clinicians and patients, this has direct implications: the number needed to treat with any future Lp(a)-lowering therapy shrinks dramatically as patients age, making elderly adults the group most likely to experience meaningful event reduction. Screening younger adults still identifies lifetime risk, but intervention priority should weight heavily toward those over 70.
Caveats include that this is an observational cohort from a predominantly White European population, limiting generalizability. The full paper was not available for review; this summary is based on the abstract alone.
Key Findings
- Absolute ASCVD risk from high Lp(a) rises 15-fold between ages 20–49 and 80–100 years.
- Relative risk from Lp(a) is uniform across age groups and sexes, with hazard ratios of 1.12–1.18 per 50 mg/dL.
- Adults aged 80–100 with very high Lp(a) face ~48 additional ASCVD events per 1,000 person-years.
- Men showed slightly higher absolute risk increases than women at every age decade.
- Older adults are likely to gain the greatest absolute benefit from emerging Lp(a)-lowering therapies.
Methodology
Prospective cohort study of 103,341 adults aged 20–100 from the Copenhagen General Population Study with median 12.5-year follow-up. Age-stratified incidence rates and Cox proportional hazard ratios for ASCVD were calculated, with secondary stratification by sex.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The cohort is predominantly White and European, limiting generalizability to other ethnicities. Observational design cannot confirm causality, though Mendelian randomization studies broadly support Lp(a) as a causal risk factor.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: